Dravet
syndrome is a
form of severe myoclonic epilepsy that occurs in infants during their first
year of age. If left untreated, it can be associated with other types of
seizures, and status epilepticus.
Children
having Dravet syndrome are generally observed with poor cognitive skills and
hyperactivity. It severely affects the person’s quality of life and around
10-20% of the patient are estimated to die due to the condition. Absence
seizures, tonic-clonic seizures, atonic seizures, and myoclonic seizures are
some other types of seizure associated with Dravet syndrome.
Request to Get Free Sample Pages at:
Zogenix Inc.
is in the process of developing ZX008 as a serotonin receptor agonist for the
treatment of Dravet syndrome. Ovid Therapeutics Inc. is also in the process of
developing OV 935, a CH24H inhibitor, for the management of this medical
condition. Insys Therapeutics Inc., and SAGE Therapeutics Inc. are some other
major players having pipeline drugs for Dravet syndrome.
Make
Enquiry Before Buying the Report:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment